Drugs / STRO-006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07807345 | Sep 2026 → Feb 2028 expected | breast cancer, colorectal cancer, endometrial cancer, esophageal cancer +4 | Sutro Biopharma, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-21 | Sutro Biopharma, Inc. | Results AACR Annual Meeting 2026 – Presentation and Posters sutrobio.com ↗
STRO-006: An Integrin beta-6–targeting ADC demonstrates favorable safety profile and potent antitumor activity in preclinical solid tumors |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-21 | Sutro Biopharma, Inc. | AACR Annual Meeting 2026 – Presentation and Posters sutrobio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STRO-006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07807345 ↗ |
| Route | Intravenous | “IV infusion” NCT07807345 ↗ |